Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons | Zendy

Christine RummelKluge | Zendy; Katja Komossa | Zendy; Sandra Schwarz | Zendy; Heike Hunger | Zendy; Franziska Schmid | Zendy; Werner Kissling | Zendy; John M. Davis | Zendy; Stefan Leucht | Zendy

Open Access

Second-Generation Antipsychotic Drugs and Extrapyramidal Side Effects: A Systematic Review and Meta-analysis of Head-to-Head Comparisons

Author(s) -

Christine RummelKluge,

Katja Komossa,

Sandra Schwarz,

Heike Hunger,

Franziska Schmid,

Werner Kissling,

John M. Davis,

Stefan Leucht

Publication year - 2010

Publication title -

schizophrenia bulletin

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.823

H-Index - 190

eISSN - 1745-1707

pISSN - 0586-7614

DOI - 10.1093/schbul/sbq042

Subject(s) - ziprasidone , quetiapine , amisulpride , olanzapine , sertindole , clozapine , risperidone , extrapyramidal symptoms , antipsychotic , positive and negative syndrome scale , medicine , aripiprazole , psychology , akathisia , atypical antipsychotic , psychiatry , pharmacology , schizophrenia (object oriented programming) , psychosis

While all second-generation antipsychotics (SGAs) are promoted for having a low risk of extrapyramidal side effects (EPS), clinical observations suggest differences between the various agents. Nevertheless, this question has never been examined in a systematic review and meta-analysis of head-to-head comparisons.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research